Talk Bio

Unnatural Products announced a research collaboration and licensing agreement with Novartis on February 18, 2026, for an undisclosed program targeting cardiovascular disease 1 2 4 . The deal includes up to $100 million in upfront and pre-IND milestone payments, plus up to $1.7 billion in development, regulatory, and commercial milestones, with tiered royalties in mid-single to low double-digits on net sales 1 2 3 4 . Novartis will handle IND-enabling studies, clinical development, manufacturing, and global commercialization 1 2 . Unnatural Products uses an AI-enhanced platform combining molecular design, parallel synthesis, and screening to develop orally-delivered macrocyclic peptides for undruggable targets 2 3 4 . This follows prior partnerships with argenx ($1.5B+), Merck ($220M), and BridgeBio 3 4 6 . UNP raised $32M in Series A in 2023 and $6M seed in 2019 3 7 . Sources: 1. https://www.marketscreener.com/news/unnatural-products-in-pact-with-novartis-to-develop-macro...